Joseph Ciaffoni - Dec 21, 2023 Form 4 Insider Report for COLLEGIUM PHARMACEUTICAL, INC (COLL)

Role
President and CEO, Director
Signature
/s/ Colleen Tupper as Attorney-In-Fact For Joseph Ciaffoni
Stock symbol
COLL
Transactions as of
Dec 21, 2023
Transactions value $
-$39,398
Form type
4
Date filed
12/22/2023, 04:36 PM
Previous filing
Dec 20, 2023
Next filing
Feb 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction COLL Common Stock Options Exercise $93K +4.36K +1.58% $21.34 279K Dec 21, 2023 Direct F1
transaction COLL Common Stock Sale -$132K -4.36K -1.56% $30.38 275K Dec 21, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COLL Stock Option (Right to Purchase) Options Exercise $0 -4.36K -20.52% $0.00 16.9K Dec 21, 2023 Common Stock 4.36K $21.34 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2023.
F2 The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.13 to $30.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2021, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the Reporting Person's continued service with the Issuer.